Announced
Completed
Financials
Tags
Biotechnology
Minority
Completed
United States
Public
medical genetics
Friendly
Acquisition
Domestic
Private Equity
Venture Capital
gene therapy
Synopsis
T. Rowe Price, a holding company that manages a group of 156 mutual funds, led a $110m Series C funding round in Generation Bio, a biotechnology company. The round had participation from investors Farallon, Wellington Management Company and existing investors Atlas Venture, Fidelity, Invus, Casdin, Deerfield and Foresite Capital. "Our vision is to develop re-dosable long-lasting gene therapies manufactured at a scale that leaves no patient or family behind. Since our founding, we have had the support of high-quality investors who share our excitement about our potential to lead a new generation of gene therapy as we advance our lead programs toward the clinic," Geoff McDonough, Generation Bio CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.